Novozymes adjusted net profit excl. PPA rises 8% in H1 FY26; adjusted EBITDA margin climbs 30 bps to 37.7%

Reuters2026/08/19 15:42

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Novozymes posted 8% organic sales growth in H1 2026, including a ~1.5 percentage-point drag from exiting certain countries.
Adjusted EBITDA margin edged up 30 basis points year-on-year to 37.7%, despite a currency headwind.
Adjusted net profit excluding PPA rose 8% from a year earlier.
Free cash flow before acquisitions came in at 14% of sales; NIBD/EBITDA was 1.8x, with CAPEX at 9.7% of sales.
Raised 2026 organic sales growth outlook to 7%-8%; expects adjusted EBITDA margin at the higher end of 37%-38%.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Novozymes A/S published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608191141OMX_____CNEWS_EN_GNW1001258382_en) on August 19, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Novozymes adjusted net profit excl. PPA rises 8% in H1 FY26; adjusted EBITDA margin climbs 30 bps to 37.7%

You may also like

Crypto prices